Regeneron Pharmaceuticals rose 15.3% over the past week to $927.89, a move that left most of its closest biotech peers well behind: GILD gained 9.4%, VRTX 6.7%, and AMGN 6.1%, while KNSA was the only peer to come close, adding 20.2% on its own separate catalyst. The Q3 earnings release on October 30 was clearly the trigger, and…
REGN upgraded to Buy by UBS with $978 price target, implying 26% upside from $778 close.
Key data as of 10 Nov 2026
REGN upgraded to Buy by UBS with $978 price target, implying 26% upside from $778 close.
REGN cost to borrow surges to 0.44%, up 237% in one week.
Regeneron Pharmaceuticals picked up a meaningful endorsement from UBS on October 15. The upgrade arrived as short sellers have been quietly pulling back, and with Q3 earnings just 15 days away. UBS analyst Trung Huynh…
Regeneron Pharmaceuticals heads into the final weeks of summer with a 20% one-month rally behind it and options traders turning noticeably more defensive — the sharpest tension in the setup right now. The clearest…
Regeneron Pharmaceuticals heads into its June 12 earnings report with analysts cutting price targets across the board and the stock nursing a 14% loss over the past month. The analyst picture is the clearest signal of…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for REGN — free to start on ORTEX.
Sign up for free →Open REGN on ORTEX